|
|
The epidemiology of HDL-C and cardiovascular disease: Does HDL indeed protect against atherosclerotic events?
|
|
|
|
LDL lowering
|
|
|
|
Statins effect on CAD risk
|
|
|
|
Low HDL-C and CVD risk
|
|
|
|
TNT: Events in HDL-C and LDL-C quintiles
|
|
|
|
Why does HDL-C protect?
|
|
|
|
HDL-C
|
|
|
|
Reverse Cholesterol
|
|
|
|
Production, maturation and metabolism of HDL
|
|
|
|
When serum induces more efflux, prognosis is worse
|
|
|
|
ApoA-I is the major protein
|
|
|
|
Heterozygosity for ApoAIL178P biochemistry
|
|
|
|
Heterozygosity for ApoA-IL178P event-free survival in carriers vs non-carriers
|
|
|
|
ApoAI based therapies
|
|
|
|
Production, maturation and metabolism of HDL
|
|
|
|
ABCAI heterozygotes and endothelial dysfunction
|
|
|
|
ABCAI heterozygotes and risk for CAD
|
|
|
|
Results
|
|
|
|
Results-increased outward
|
|
|
|
Results-more plaque
|
|
|
|
Conclusions
|
|
Dr. Kees Hovingh
Hovingh (PPTX 13.7MB)
Share this page with your colleagues and friends: